Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria

Hepatology

Volumn 61, Issue 6, 2015, Pages 1968-1977

  Yao, Francis Y ^a   Mehta, Neil ^a   Flemming, Jennifer ^a   Dodge, Jennifer ^a   Hameed, Bilal ^a   Fix, Oren ^a   Hirose, Ryutaro ^a   Fidelman, Nicholas ^a   Kerlan, Robert K ^a   Roberts, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHILD TURCOTTE PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RETROSPECTIVE STUDIES; SAN FRANCISCO; YOUNG ADULT;

EID: 84929607079     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27752     Document Type: Article

References (33)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
4. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:11-22.
5. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:249-251.
6. Yao FY, Ferrell L, Bass NM, Watson JJ, Bachetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma; expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
7. Duffy JP, Vandanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. A 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-511.
8. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features. Analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006;12:1761-1769.
9. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
10. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846.
11. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011;17(Suppl 2):S109-S116.
12. Yao FY, Kerlan RK, Jr., Hirose R, Davern TJ, III, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827.
13. Lo CM. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion? Am J Transpl 2008;8:2485-2486.
14. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
15. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
16. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954;1:462-503.
17. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
18. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of pre-operative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688-701.
19. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transpl 2008;8:2547-2557.
20. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transpl 2009;9:1158-1168.
21. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transpl 2009;9:1920-1928.
22. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010;16:289-299.
23. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248:617-625.
24. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563.
25. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
26. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010;16:925-929.
27. Kwan SW, Fidelman N, Ma E, Kerlan RK, Jr., Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012;18:727-736.
28. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013;19:1343-1353.
29. Hakeem AR, Young RS, Marangoni G, Lodge JPA, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:987-999.
30. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-984.
31. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein >1000 ng/mL as an exclusion criterion for liver transplant in patients with hepatocellular carcinoma meeting Milan criteria. Liver Transpl 2014;20:945-951.
32. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumor progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108-1118.
33. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011;53:1580-1589.